

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

NCT07020533

Status	RECRUITING
Phase	Phase 1
Sponsor	City of Hope Medical Center
Enrollment	46 participants

Key Eligibility Criteria

Inclusion (43)

- DONORS: Documented informed consent of the participant. This can be done in person or informed consent can be obtained remotely.
- Remote consent, when appropriate, will be obtained per institutional guidelines.
- Assent, when appropriate, will be obtained per institutional guidelines.
- Adult subjects who require a legally authorized representative (LAR) will not be permitted to be enrolled under this protocol.
- DONORS: Age: 18 - 75.

... and 38 more (see full listing online)

Exclusion (27)

- DONORS: Any prior transplant to day 1 of protocol therapy (day 1 defined as the day after donors receive the Triplex vaccine).
- DONORS: Chemotherapy, radiation therapy, biological therapy, immunotherapy within 21 days prior to day 1 of protocol therapy.
- DONORS: Receipt of any vaccine (licensed or investigational) within 30 days prior to and after the study vaccine.
- DONORS: Unfit to undergo standard stem cell mobilization and apheresis e.g. abnormal blood counts, history of stroke, uncontrolled hypertension.
- DONORS: Sickling hemoglobinopathy including hemoglobin (Hb)SS, HbAS, HbSC.

... and 22 more (see full listing online)

Locations (3 total)

City of Hope Medical Center, Duarte, California, United States
Northside Hospital, Atlanta, Georgia, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States